Cargando…
The Effects of Dapagliflozin in Patients With Heart Failure Complicated With Type 2 Diabetes: A Meta-Analysis of Placebo-Controlled Randomized Trials
BACKGROUND: Cardiovascular disease threatens the health and quality of life of individuals, particularly those with type II diabetes. Recently, some studies have reported the effect of sodium-glucose cotransporter 2 (SGLT2) inhibitors in reducing the rates of hospitalization or urgent visits, result...
Autores principales: | Zhai, Miaobo, Du, Xin, Liu, Changmei, Xu, Huipu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10012068/ https://www.ncbi.nlm.nih.gov/pubmed/36994345 http://dx.doi.org/10.3389/fcdhc.2021.703937 |
Ejemplares similares
-
Dapagliflozin, as Add-on Therapy in Type 2 Diabetes Patients, Is Associated With a Reduction in Albuminuria and Serum Transaminase Levels
por: Benjamin, Silas, et al.
Publicado: (2021) -
Liraglutide Lowers Palmitoleate Levels in Type 2 Diabetes. A Post Hoc Analysis of the LIRAFLAME Randomized Placebo-Controlled Trial
por: Wretlind, Asger, et al.
Publicado: (2022) -
Dapagliflozin Versus Placebo on Left Ventricular Remodeling in Patients With Diabetes and Heart Failure: The REFORM Trial
por: Singh, Jagdeep S.S., et al.
Publicado: (2020) -
The role of maternal DNA methylation in pregnancies complicated by gestational diabetes
por: Dias, Stephanie, et al.
Publicado: (2022) -
Global Epidemiology, Health Outcomes, and Treatment Options for Patients With Type 2 Diabetes and Kidney Failure
por: Phillips, Jessica, et al.
Publicado: (2021)